Fibrogen Inc Stock Price, News & Analysis

FibroGen, Inc. (NASDAQ: FGEN) will release its first quarter 2023 financial results on May 8, 2023, following the market's close. A conference call is scheduled for 5:00 PM ET on the same day to discuss the company's performance with investors. FibroGen specializes in biopharmaceuticals, focusing on developing innovative therapeutics, including Pamrevlumab for treating idiopathic pulmonary fibrosis and various cancers, and Roxadustat, which is approved for managing anemia due to chronic kidney disease. Roxadustat is currently in Phase 3 clinical trials for additional anemia indications. Interested parties can access the conference call through the company's Investor Relations page or via phone. A replay will be provided afterward.

Foresee Pharmaceuticals announced the appointment of Dr. Bassem Elmankabadi as Senior Vice President of Clinical Development on April 17, 2023. Dr. Elmankabadi brings over 17 years of clinical experience, previously holding leadership roles at Amgen (NASDAQ: AMGN) and FibroGen (NASDAQ: FGEN). His experience includes negotiating four Clinical Development Plans for Phase 2 and 3 studies for the company's drugs, Cudetaxestat and Pamrevlumab. Dr. Elmankabadi's background includes surgical leadership and clinical instruction at UCLA. Foresee Pharmaceuticals focuses on innovative therapies, with key products including CAMCEVI for advanced prostate cancer, approved in the U.S., Canada, and EU, as well as other promising candidates in clinical development.

FibroGen, Inc. (NASDAQ: FGEN) has successfully completed enrollment of 372 patients in its Phase 3 clinical trial, ZEPHYRUS-2, targeting idiopathic pulmonary fibrosis (IPF). This trial, which is randomized, double-blind, and placebo-controlled, aims to assess the efficacy and safety of pamrevlumab over a 48-week period, with top-line results expected in mid-2024. The company's Chief Medical Officer expressed optimism for new treatment options for IPF patients. FibroGen is also conducting another Phase 3 trial, ZEPHYRUS-1, with data anticipated in mid-2023, furthering their commitment to addressing unmet medical needs in fibrotic diseases.

FibroGen reported 2022 total revenue of $140.7 million, down from $235.3 million in 2021. Fourth-quarter revenue was $34.4 million, compared to $16.5 million year-over-year. Roxadustat sales in China reached $82.9 million, a 74% increase from 2021, with total sales in the fourth quarter at $53.1 million, up 328%. The company anticipates key trial data releases in 2023 for treatments, including pamrevlumab and roxadustat. FibroGen has $442.7 million in cash and equivalents, sufficient to fund operations through mid-2024 without additional financing.

FibroGen (NASDAQ: FGEN) announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference held in Boston from March 5-8, 2023. The panel will focus on Respiratory/Infections and is scheduled for March 8, 2023, at 10:30 AM Eastern Time. Investors can access a live audio webcast on the FibroGen Investor webpage, with a replay available for approximately 30 days. FibroGen continues to innovate in biopharmaceuticals, focusing on therapies for conditions such as idiopathic pulmonary fibrosis and anemia associated with myelodysplastic syndromes.